EXHIBIT 4.5 CONSULTING AGREEMENT ("AGREEMENT") -------------------- AGREEMENT entered into as of October 30, 1997, between Kinexsys and Bentley Pharmaceuticals (hereinafter, the "Company"). 1. Consulting Duties Implement an investor interest program...Consulting Agreement • June 15th, 1999 • Bentley Pharmaceuticals Inc • Pharmaceutical preparations • California
June 20, 1997 BENTLEY PHARMACEUTICALS, INC. The Transferability of this Warrant is Restricted as Provided in Article 3 In consideration of $.001 per Warrant and other good and valuable consideration, the receipt of which is hereby acknowledged by...Bentley Pharmaceuticals Inc • June 15th, 1999 • Pharmaceutical preparations
EXHIBIT 4.2.2 Addendum #1 to Consulting Agreement Dated October 23, 1996 Between Plexus Ventures, Inc. and Bentley Pharmaceuticals The second paragraph of the section "Success Fees", page two of the Agreement is expanded to read as follows: Plexus...Bentley Pharmaceuticals Inc • June 15th, 1999 • Pharmaceutical preparations
Plexus Ventures will have the option to receive success fees in shares of Bentley Pharmaceuticals, in cash or in a combination of the two. The value of Bentley shares for this purpose will be calculated, on a transaction by transaction basis, as the average of the daily closing prices for the 20 trading days immediately preceding the signing dates of Letters-of Intent, or equivalent undertakings, confirming the transactions.
EXHIBIT 4.2.3 PLEXUS VENTURES, INC. November 24, 1997 Mr. James R. Murphy Chairman and CEO Bentley Pharmaceuticals, Inc. 4830 West Kennedy Boulevard Suite 550 Tampa, FL 33609 Dear Jim: We are pleased to offer this letter Agreement as evidence of the...Bentley Pharmaceuticals Inc • June 15th, 1999 • Pharmaceutical preparations
